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Abstract
Background: Mindfulness based stress reduction (MBSR) is increasingly being used to improve outcomes such as
stress and depression in a range of long-term conditions (LTCs). While systematic reviews on MBSR have taken
place for a number of conditions there remains limited information on its impact on individuals with Parkinson’s
disease (PD).
Methods: Medline, Central, Embase, Amed, CINAHAL were searched in March 2016. These databases were searched
using a combination of MeSH subject headings where available and keywords in the title and abstracts. We also
searched the reference lists of related reviews. Study quality was assessed based on questions from the Cochrane
Collaboration risk of bias tool.
Results: Two interventions and three papers with a total of 66 participants were included. The interventions were
undertaken in Belgium (n = 27) and the USA (n = 39). One study reported significantly increased grey matter
density (GMD) in the brains of the MBSR group compared to the usual care group. Significant improvements were
reported in one study for a number of outcomes including PD outcomes, depression, mindfulness, and quality of
life indicators. Only one intervention was of reasonable quality and both interventions failed to control for potential
confounders in the analysis. Adverse events and reasons for drop-outs were not reported. There was also no
reporting on the costs/benefits of the intervention or how they affected health service utilisation.
Conclusion: This systematic review found limited and inconclusive evidence of the effectiveness of MBSR for PD
patients. Both of the included interventions claimed positive effects for PD patients but significant outcomes were
often contradicted by other results. Further trials with larger sample sizes, control groups and longer follow-ups are
needed before the evidence for MBSR in PD can be conclusively judged.
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Background
Parkinson’s disease (PD) is a chronic neurodegenerative
disease generally conceptualised as affecting motor func-
tion [1]. However, those with PD often face additional
‘non-motor symptoms’ (NMS), such as mental health co-
morbidities including depression and anxiety [2, 3]. These
NMS have been associated with reduced quality of life in
PD [4]. Depression and anxiety can also exacerbate the
symptoms of PD [2, 5]. Therefore it is important to con-
sider how therapies that can treat the symptoms of anxiety
and depression, and increase resilience to stress may be
beneficial to PD patients in dealing with their condition.
People with PD have been found to be open to non-
pharmacological treatment interventions [6, 7].
Mindfulness based stress reduction (MBSR) is an ap-
proach which is increasingly being used on people with
long-term conditions. MBSR was first conceptualized and
used by Jon Kabat-Zinn [8] and was developed as a com-
plementary intervention in a hospital setting to serve as a
referral service to physicians and other health care pro-
viders for patients with chronic pain or multiple chronic
conditions who were not responding sufficiently to stand-
ard treatments [9]. MBSR and related approaches have
also been associated with improvements for a range of
conditions [10]. Reviews have demonstrated improve-
ments in symptoms amongst people with cancer [11, 12]
pain [13, 14] cardiovascular disease [15], stroke [16] and
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multiple sclerosis [17]. Improvements have included men-
tal health outcomes, such as depression, stress and anx-
iety, as well as overall quality of life. Despite the potential
benefits MBSR might have, no previous review has been
undertaken to determine the effects of MBSR for the
treatment of those with PD. Therefore, this systematic re-
view aimed to determine the effectiveness of MBSR for
patients suffering from PD.
Methods
A registered protocol (PROSPERO 2016: CRD4
2016035304) guided the conduct of this review [18],
which is reported in adherence to the Preferred Report-
ing Items for Systematic Reviews and Meta-analyses
(PRISMA) Statement [19].
Eligibility criteria
Inclusion criteria were based on the study design, par-
ticipants, interventions and outcomes (SPIO), as de-
scribed below. SPIO is an adaptation of the PICO
(Population, Interventions, Comparison, Outcomes)
framework [20] https://library.med.nyu.edu/library/in-
struction/handouts/pdf/picohandout.pdf. Trials which
solely focus on, or incorporate a mindfulness interven-
tion as defined by the author were selected. The popu-
lation was adults diagnosed with PD. As with many
other mind-body interventions, mindfulness as a thera-
peutic intervention is inherently varied and heteroge-
neous. Thus different forms, duration and frequency of
mindfulness interventions were included. We included
both Randomised Controlled Trials (RCTs) and non-
randomised controlled trials which reported quantita-
tive outcomes. Finally, we only considered studies pub-
lished in peer-reviewed journals in English, as evidence
suggests that limiting studies in this way does not
introduce significant bias but is associated with consid-
erable resource savings [21].
Information sources and search strategy
The following databases were searched: CENTRAL
(Cochrane), Medline, Embase, Amed, PsycINFO and
CINAHL.
These databases were searched using a coMBSRnation
of subject headings where available (such as MeSH) and
key words relating to Mindfulness and PD. The search
strategy was developed for use in Medline, and was
amended for use in the other databases, using appropri-
ate controlled vocabulary, Boolean operators and search
symbols. The search was complemented by carrying out
citation searches for included studies. We also scanned
the reference lists of related reviews for potentially rele-
vant papers.
Study selection
Following de-duplication, bibliographic records (titles and
abstracts) were downloaded into the Distiller software
programme https://www.evidencepartners.com/products/
distillersr-systematic-review-software/ Abstracts and full
papers were screened against the inclusion criteria, by two
reviewers working independently. Inter-reviewer disagree-
ments were resolved by discussing whether the paper met
the inclusion/exclusion criteria. If consensus between the
reviewers was not possible, the decision was referred to a
third party.
Data extraction
We used online data collection forms using Distiller SR
software. Two independent researchers extracted data
on study details (country of origin, inclusion/exclusion
criteria, number of participants), participant details
(mean age, % male, ethnicity, socio-economic status,
smoking status and comorbidities), description of the
intervention, and outcomes.
Assessment of methodological quality
We based assessment of quality on measures from the
Cochrane collaboration tool for assessing bias [22] Qual-
ity was assessed in each of the included studies by the
two researchers working independently. Methods of allo-
cation concealment, randomisation procedure, dropout
rate and whether there was evidence of selective out-
come reporting were assessed by answering yes, no or
unknown.
Meta-analysis was planned if sufficient homogeneous
studies were available for statistical pooling. However, as
only 2 studies (3 papers) were included and were of dif-
ferent designs with one reporting results compared to a
control group and one having no control group, meta-
analysis was not possible.
Results
Our initial search identified 1336 papers. After title and
abstract screening there were 15 papers for full paper re-
view. Three papers from two interventions met our cri-
teria and were included (see Fig. 1).
Description of included studies
The two studies included a total of 66 participants, with
27 and 39 participants per study respectively (see Table 1).
They took place in the USA [23] and Belgium [24, 25].
The studies differed considerably in the nature and deliv-
ery of the intervention and the outcome measures used.
One study was a randomised control trial and one a non-
randomised trial. The studies were similar in the age pro-
file of the participants with mean age ranging from 61.8
[24, 25] to 65.6 [23]. Only one study reported the ethnicity
of the participants and showed they were predominantly
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Caucasian [23]. Both studies had a majority of men ran-
ging from 51.9% [24, 25] to 58.3% [23].
Aims of the interventions
Cash et al. [23] was a pilot study of the feasibility and im-
pact of an 8-week mindfulness-based group intervention
on cognitive and emotional functioning for individuals with
PD and their caregivers. The Picket et al. [24, 25] study pro-
duced two papers from the same intervention. The
principal aim of one was to investigate structural changes
on brain MRI using voxel based morphometry (VBM) [24]
while the other investigated possible neurobehavioral and
neuroplastic changes secondary to taking part in mindful-
ness training for individuals living with PD [25].
Description of interventions
A summary of the key components of the interventions is
given in Table 2. Both studies used MBSR interventions
Fig. 1 Flowchart for PD review
Table 1 Characteristics of included papers
Author (Year)
Location
Population
Numbers
Mean
Age (SD)
Ethnicity Main Outcomes assessed Main results
Cash at al
[22]
2016
USA
39 (21 men
(53.8%) 18
women)
65.6 (7.6) 89.7%
Caucasian
Apathy (Apathy Scale),
depression (Patient Health
Questionnaire-9); anxiety
(Generalized Anxiety Disorder-7)
Mindfulness levels significantly increased for all participants
from pre- too immediate- to post. A significant
improvement was seen for self –reported symptoms of
depression and self-reported language functioning. Also
showed significant improvement on mental flexibility and
complex attention tasks and reported significantly fewer
emotional and cognitive symptoms associated with PD.
Pickut et al.
[23]
2013
Belgium
27 (14
(51.9%) men
13 women)
61.8 (9.1) N/I MRI data sets of the brain were
obtained at baseline and after 8
weeks’ follow-up. VBM analysis
was performed using DARTEL from
the SPM8 software. The resulting
difference maps were statistically
compared to examine grey matter
density (GMD) differences.
Increased GMD was found in the MBSR compared to the
UC group in the region of interest analysis in the right
amygdala, and bilaterally in the hippocampus. Whole brain
analysis showed increased GMD in the left and right
caudate nucleus, the left occipital lobe at the lingual gyrus
and cuneus, the left thalamus, and bilaterally in the
temporo-parietal junction. In contrast, GMD differences
were found in the UC group in the left anterior lobe and
dentate nucleus of the cerebellum.
Pickut et al.
[24]
2015
Belgium
27 (14 men
13 women)
61.8 (9.1) N/I Unified Parkinson’s Disease Rating
Scale, Five Facet Mindfulness
Questionnaire, PDQ-39, Beck
Depression Inventory (BDI)
Significant changes after the MBSR were found including
a 5.5 point decrease. On the UPDRS motor score, an
increase of 0.79 points on Parkinson’s disease
questionnaire (PDQ-39) pain item, and a 3.15 point
increase in the Five Facet Mindfulness Questionnaire
observe facet.
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that were based the original MBSR program developed at
the University of Massachusetts. [23–25].
Adaptations to the standard 8-week long program plan
were varied across the studies. One study used sessions
of shorter duration i.e. 1.5 h [23] compared to the trad-
itional 2.5 h. The Cash et al. study [23] also used a later
timing for the retreat at 1 week after the eighth session;
the retreat session also had a shorter duration, at half a
day, than the 1-day format generally used for MBSR
programs. In contrast, Pickut et al. offered no full day
retreat [24, 25].
All studies offered psycho-education, mindful medita-
tions (sitting meditation, walking meditation) and gentle
yoga. Cash et al. [23] encouraged participants to modify
techniques as needed to meet their personal needs and
limitations, such as sitting in a chair or lying down to
optimize physical comfort and safety, or practicing chair
yoga rather than floor-based exercises if unable to get up
safely from the floor [23]. Both studies contained
instructions for home study for the duration of the
course [23–25].
Quality appraisal
Details of the quality appraisal of the included studies
can be found in Table 3. Only one intervention had a
control group (usual care) and was therefore the only
study considered to have a correct randomisation pro-
cedure [24, 25]. Allocation concealment was also clear in
this intervention. One study had a dropout rate greater
than 20% [23]. Both studies were adjudged not to have
controlled appropriately for potential confounders in
their analysis. In addition, study samples were relatively
small in size, meaning that they were likely to be under-
powered.
Outcomes
PD measures
The impact on PD was measured by Pickut et al. [25]
using the Unified Parkinson’s Disease Rating Scale
(UPDRS) [26]. The investigator scoring, including UPDRS
motor scoring was performed by a movement disorders
specialist who was blinded as to the study allocation arm
of the participant in question. Each question has a 5-point
scale, where 0 means an absence of symptoms and 5 rep-
resents the most severe symptoms. They found significant
change was obtained for the UPDRS motor III score
(F = 4.39, p < .05), demonstrating motor changes for the
MBSR group (pre-M = 27.43 versus post-M = 21.93),
while no significant changes could be obtained for the UC
group (pre-M = 27.92 versus post-M = 29) [25]. This re-
vealed that after the MBSR a decrease of 5.5 (20.05%)
points was found on the UPDRS motor score. Cash et al.
[23] assessed non-motor function using the PD Non
motor Symptoms Questionnaire [27] but found no signifi-
cant differences.
Depression
Two of the studies assessed the impact on depression
using two different measures [23, 28]. Cash et al. [23]
used the Patient Health Questionnaire-9 [29] and found
that participants showed significant declines in their re-
port of depression symptoms, F (1, 24) =6.31, p = .019,
η2 = .21. However, Pickut et al. [25] used the Beck
Depression Inventory (BDI) [30] and found no signifi-
cant difference.
Anxiety
Cash et al. [23] assessed the impact on anxiety using the
Generalized Anxiety Disorder-7 [31] scale but found no
significant differences.
Quality of life measures
Both Cash et al. [23] and Pickut et al. [25] used the
Parkinson’s disease questionnaire (PDQ-39) [32] which
is a subjective questionnaire to assess quality of life in
patients with PD. The questionnaire consists of 39 ques-
tions, which are divided into eight subscales (mobility,
ADL, emotional well-being, stigma, social support, cog-
nition, communication, and bodily discomfort). Each
question has a range from 0 (no problem) to 100 (con-
tinuous problem/unable to do it). Cash et al. [23] re-
ported that significant improvements were seen on the
emotional functioning, F (1, 25) =10.34, p = .004,
η2 = .29, and cognitive functioning, F (1, 25) =4.50,
p = .044, η2 = .15, subscales. Pickut et al. [25] found that
a marginally significant interaction effect (F = 3.50,
p = .07) was obtained for the Parkinson’s disease ques-
tionnaire (PDQ-39) pain score, suggesting an increase of
0.79 (10.53%) points for the MBSR group and a decrease
Table 2 Description of Interventions
Author
(Year)
Location
Intervention Description
Cash at al
[22]
2016
USA
MBSR Participants were enrolled in 7–10 person
groups that met weekly for 1.5-h-long
sessions for 8 weeks at an interdisciplinary
movement disorders clinic in a large, private
room. The program included a half-day (4 h)
silent retreat taking place approximately
1 week after the eighth session to encour
age participants to deepen their practice by
providing time for longer practices in a
group setting.
Pickut et al.
[23, 24]
2013
Belgium
MBSR The intervention consisted of 2.5 h meetings
on eight consecutive weeks. The
intervention did not include an all day
session. Audio recordings containing 45-min
guided mindfulness exercises (meditation,
body scan, mindful movement) were given
with instructions for daily home practice
corresponding to the course sequence.
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of 0.69 (8.63%) for the usual care group. However, no
significant changes were found for the overall (PDQ-39)
score for either study.
Apathy
Cash et al. [23] used the Apathy scale [33] to measure
changes in apathy but found no significant changes in
levels.
Mindfulness
Both Cash [23] and Pickut et al. [25] used Five Facet
Mindfulness Questionnaire [34] (FFMQ) of 39 items;
five domains of mindfulness “skills” are assessed: observ-
ing, describing, acting with awareness, non- judging of
inner experience, and non-reactivity to inner experience.
Items are rated on a 5-point Likert-type scale from
“never or very rarely true” to “very often or always true.”
The adding up of domain results in a total score gives
an approximation of mindfulness “skills.” Cash et al. [23]
found no significant changes. Picket et al. [25] found a
significant interaction effect (F = 11.07, p < .01) was ob-
tained for the FFMQ ‘observe’ facet of the scale indicat-
ing that for the MBSR group there was a significant
increase after treatment (M = 27.29) in comparison with
before treatment (M = 24.14). For the UC group, no dif-
ference was obtained between before (M = 23.69) and
after treatment (M = 23.54). No significant effect was
obtained for the other facets of the FFMQ.
Brain magnetic resonance imaging (MRI)
Picket et al. [24] evaluated the neuroplastic effects of
MBSR on the brain using anatomical MRI scans, asses-
sing voxel-based morphometry (VBM). T1-weighted
data sets were segmented into gray matter (GM), white
matter (WM) and cerebrospinal fluid (CSF), using a uni-
fied tissue segmentation approach. For each individual
patient, the registered baseline T1-weighted image was
subtracted from the 8 weeks’ follow-up T1-weighted
image to obtain images that represent changes over time
for each patient. These subtracted images were then
compared between both intervention groups using a T-
test. MRI findings showed increased GMD in the MBSR
group compared to the UC group overtime in the left
and right hippocampi and a small region in the right
amygdala. Whole brain analysis revealed a large cluster
in the right caudate nucleus and a smaller cluster in the
left caudate nucleus. Significant clusters were also found
in the left occipital lobe at the lingual gyrus and cuneus,
in the left thalamus and bilaterally in the tempero-
parietal junction. However, increased GMD was found
in the UC compared to the MBSR group in the anterior
lobe and dentate nucleus of the left cerebellum.
Discussion
This systematic review found only limited evidence that
MBSRs can prove useful in PD patients due to the small
number and nature of the studies that were eligible for
inclusion. Both of the included interventions claimed
positive effects for PD patients. These findings are also
supported by a qualitative study of 12 people with PD
which found that participation in a mindfulness-based
intervention helped with making positive changes to
coping responses and could benefit people with PD and
was an acceptable form of group intervention. [35] How-
ever, where studies reported on similar outcomes, differ-
ences in results were found. Pickut et al. [25] found that
the intervention improved PD outcomes in contrast to
Cash et al. [23] who found no significant effects. Simi-
larly, Pickut et al. [25] reported an improvement in
mindfulness measured with the FFMQ but Cash et al.
[23] found no significant changes with the same meas-
ure. Conversely, Cash et al. [23] reported an improve-
ment in depression, but Pickut et al. [25] found no
significant difference. Pickut et al. [24] found signifi-
cantly increased grey matter density (GMD) in the
MBSR group compared to the usual care group. How-
ever, the authors recognise that the effects of this signal
increase need to be correlated with motor and non-
motor symptoms of PD and until further studies verify
this effect the evidence for beneficial effects for PD pa-
tients remains limited [24].
Methodological and quality differences between the in-
cluded studies might explain some of the differences in
results. Only one study [24, 25] used a control group
(usual care) making it difficult to draw definite conclu-
sions from the other study about the likley causal effect
of the intervention and changes in outcomes found [28].
Both studies where small in size, and only one was of
Table 3 Quality appraisal for included studies
Author (Year) Appropriate Randomisation
Technique
Allocation
concealment
Dropout
rate < 20%
Potential confounders properly
accounted for
Were eligibility
clear
Cash at al [22]
2016
USA
N/A N/A No No Yes
Pickut et al. [23, 24]
2013
Belgium
Yes Yes Yes No Yes
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reasonable quality [24, 25]. Adverse events and reasons
for drop-outs were not reported. This is of concern as
the safety of MBSR may be particularly important for
PD patient due to the nature of their condition [36].
There was also no reporting on the costs/benefit of the
intervention. The studies that reported on ethnicity of
the intervention subjects showed them to be largely
Caucasian, while little information on the socio-
economic status of the participants. Follow up periods
were short, with both interventions recording results im-
mediately post intervention, and thus beneficial impacts
over a longer period of time could not be determined.
Since conducting our review a recent additional small
exploratory RCT been published on an intervention that
combined mindfulness with lifestyle education [37]. This
found limited evidence of effectiveness of the interven-
tion on the primary outcome of well-being (Parkinson’s
Disease Questionnaire; PDQ-39). The author’s con-
cluded that a larger study was required.
Strength and limitations
This is the first review evaluating the effectiveness of
MBSRs in PD patients and has been carried out rigorously.
The limited number and design of the studies meant meta-
analysis was not possible. The small number of studies also
meant analysis of the possible effects of the different spe-
cific intervention components, such as shorter duration of
the sessions and no full day retreat, was not possible.
Conclusions
This systematic review found inconclusive evidence of
the effectiveness that MBSRs have for PD patients. Fur-
ther trials with larger sample size, control groups and
longer follow-up are needed before the evidence for
MBSRs in PD can be conclusively judged.
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